Atogepant
Brand names: Qulipta
At a glance
- Medicare prescriptions, 2024
- 156,281
- Medicare drug cost
- $188.9M
- Average cost per prescription
- $1,209
- Clinicians who prescribed it
- 5,373
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
QULIPTA is indicated for the preventive treatment of migraine in adults. QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.
From the FDA-approved prescribing information (label dated September 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Neurology 51.0%
- Nurse Practitioners 24.1%
- Physician Assistants 11.0%
- Family Medicine 5.3%
- Internal Medicine 3.1%
- Pain Medicine 2.0%
- Physical Medicine & Rehabilitation (PM&R) 1.1%
- Child Neurology 0.4%
- Osteopathic Manipulative Medicine 0.2%
- Psychiatry 0.2%
- Ophthalmology 0.2%
- General Practice 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2021–2024
Medicare prescriptions rose 18,236% from 2021 to 2024.
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
AbbVie Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white round tablet, 6 mm | A 10 |
| 30 mg | white oval tablet, 7 mm | A30 |
| 60 mg | white oval tablet, 9 mm | A60 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $11.0M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AbbVie Inc. $11.0M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
- Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine Enrolling by invitation · AbbVie Inc.
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine Recruiting · AbbVie Inc.
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years Recruiting · AbbVie Inc.
- Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine Active, not recruiting · AbbVie Inc.
- Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine Completed · AbbVie Inc.
- A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine Completed · AbbVie Inc.
- Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine Completed · AbbVie Inc.
- Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine Completed · AbbVie Inc.
- A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection Completed · AbbVie Inc.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.